Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The study of molecular and genetic markers of apoptosis and proliferation, their role in the treatment and prevention of osteogenic sarcoma

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Mirzagaleb Tillyashaykhov

Citation

Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299

Authors

M.N. Tillyashaykhov1, D.S. Polatova2, M. Gafur-Akhunov2, K. Abdikarimov2, U. Islamov2, R. Davletov2

Author affiliations

  • 1 Urology, National Research Center of Oncology and Radiology, 100174 - Tashkent/UZ
  • 2 Bone And Soft Tissue Sarcomas, National Research Center of Oncology and Radiology, 100174 - Tashkent/UZ
More

Resources

Background

The prognostic value of proliferative and apoptotic activity of tumors in patients with osteogenic sarcoma was investigated in order to determine which genes are involved in their pathogenesis and prognosis.

Methods

Immunohistochemical methods (IHC) were used to study the expression of p53, bcl-2, Ki-67 in patients with osteogenic sarcoma in comparison with the effectiveness of treatment. Patients with positive results of chemotherapy (group 1) underwent radiotherapy for a radical program in the total focal dose up to 60-70 Gy. When receiving a good effect from radiation therapy (group 2), patients received another 4-5 courses of chemotherapy. Surgical treatment was performed in 36 patients (41.9%) with a large pulpy component of the tumor and with ineffective chemotherapy or chemoradiotherapy (group 3).

Results

In group 1 patients, who received chemotherapy, the full effect was observed only in patients with negative and weakly positive IHC reactions to the p53 (18%), Ki-67 (16%) and bcl-2 (10%). For partial effect, the phenotype of tumor cells was as follows: negative and weakly positive IHC reaction to the mutant p53 gene was seen in 52% of patients, in Ki-67 - in 62%, and bcl-2 - in 48%. In 6% of patients in this group, the effect of therapy was negative. In the second group, only 10% of the patients had a full effect of the therapy, while in all patients, the tumor cells were mutant p53 negative, 5% had average Ki-67 and bcl2, and 5% were Ki-67 and bcl-2 negative. 25% of patients in this group had partial effects. In 20% of patients in this group, absence or weak expression of mutant p53 gene was detected in tumor cells, expression of Ki67 and bcl 2 genes in 15% was average, the remaining patients were with Ki-67 and bcl-2 negative. In group 3, 56% of patients had positive effect with therapy, among them, those with weak or no, expression of mutant gene p53 were 75% and only 12.5% showed moderate expression of this protein.

Conclusions

Our findings suggest that the study of the expression of the mutated p53 suppressor gene is a more informative prognostic factor in osteogenic sarcoma and contributes to an understanding of the mechanisms of cancer, development of new diagnostic methods and pathogenetically valid approaches to the therapy of osteogenic sarcoma.

Clinical trial identification

Legal entity responsible for the study

Ministry of Health of Republic of Uzbekistan.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

Working arrangements after cancer diagnosis: who, what, when and how?

Presenter: Caroline Alleaume

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

VOYAGER: An open-label, randomised, Phase 3 study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)

Presenter: Sebastian Bauer

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings